Log in

Relevant bibliographies by topics / Immunocheckpoint / Journal articles

To see the other types of publications on this topic, follow the link: Immunocheckpoint.

Journal articles on the topic 'Immunocheckpoint'

Author: Grafiati

Published: 1 April 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Immunocheckpoint.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rizzo, Mimma, Matteo Santoni, and Camillo Porta. "Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data." Journal of Onco-Nephrology 4, no. 3 (2020): 153–64. http://dx.doi.org/10.1177/2399369320943609.

Full text

Abstract:

Therapeutic sequencing strategies for metastatic renal cell carcinoma have evolved significantly over time. For about 10 years, vascular endothelial growth factor receptor-targeted therapies and mammalian target of rapamycin inhibitors have been the standard of care. About 5 years ago an immunocheckpoint inhibitor, nivolumab, has opened new therapeutic perspectives. Recent clinical studies have confirmed the biological rationale of combining two immunocheckpoint inhibitors or vascular endothelial growth factor-targeted therapies plus immunocheckpoint inhibitors, demonstrating an improvement in

APA, Harvard, Vancouver, ISO, and other styles

2

Singh, Navdeep, Sandeep Singh Lubana, George Constantinou, and Andrea N. Leaf. "Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma." Case Reports in Oncological Medicine 2020 (May 15, 2020): 1–5. http://dx.doi.org/10.1155/2020/7492634.

Full text

Abstract:

Immunocheckpoint inhibitor (ICI) therapy has provided significant clinical improvements in the treatment of several malignancies. The purpose of this report is to increase awareness of hypereosinophilia associated with checkpoint inhibitors, a topic that has been rarely reported. Hypereosinophilia may need to be addressed especially if eosinophil counts increase to levels where hypereosinophilic visceral complications can occur. We are presenting a case of a 57-year-old male with hypereosinophilia that was seen in the setting of progression of metastatic non-small-cell lung cancer during and a

APA, Harvard, Vancouver, ISO, and other styles

3

Borghaei, Hossein. "Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer." Annals of Oncology 28 (October 2017): ix20. http://dx.doi.org/10.1093/annonc/mdx552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Cazzato, Gerardo, Eliano Cascardi, Anna Colagrande, et al. "T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review." Cancers 15, no. 6 (2023): 1697. http://dx.doi.org/10.3390/cancers15061697.

Full text

Abstract:

T cell immunoglobulin and mucin domain 3 (TIM-3) is an inhibitory immunocheckpoint that belongs to the TIM gene family. Monney et al. first discovered it about 20 years ago and linked it to some autoimmune diseases; subsequent studies have revealed that some tumours, including melanoma, have the capacity to produce inhibitory ligands that bind to these receptor checkpoints on tumour-specific immune cells. We conducted a literature search using PubMed, Web of Science (WoS), Scopus, Google Scholar, and Cochrane, searching for the following keywords: “T cell immunoglobulin and mucin-domain contai

APA, Harvard, Vancouver, ISO, and other styles

5

Santoni, Matteo, Daniel Y. C. Heng, Gaetano Aurilio, et al. "Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma." Current Drug Targets 21, no. 4 (2020): 416–23. http://dx.doi.org/10.2174/1389450120666191017113051.

Full text

Abstract:

Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor

APA, Harvard, Vancouver, ISO, and other styles

6

Mejías, Claudia, and Osmany Guirola. "Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations." Journal of Molecular Graphics and Modelling 91 (September 2019): 105–11. http://dx.doi.org/10.1016/j.jmgm.2019.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ebata, T., T. Shimizu, S. Iizumi, et al. "Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials." Annals of Oncology 28 (November 2017): x40. http://dx.doi.org/10.1093/annonc/mdx658.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sonmez, Ozlem, Ozlem Nuray Sever, Basak Oyan, and Osman Gokhan Demir. "Immunotherapy releated cardiomyopathy." Journal of Clinical Oncology 35, no. 15_suppl (2017): e14601-e14601. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14601.

Full text

Abstract:

e14601 Background: Side effects of immunotherapies also differ from classical cytoxic chemotherapy agents such as effects. Cardiomyopathy is a relatively rare complication. Studies have shown that the risk of developing myocarditis is higher when the ipilimumab / nivolumab combination is used than when the single agent nivolumab is used. ImmunoCheckpoint inhibitors are associated with an increase in immunologic response and immunosuppressives such as corticosteroids, TNF-alpha antagonists and mycophenolate acetate are used in treatment.In this study, we aimed to report cardiac toxicity in pati

APA, Harvard, Vancouver, ISO, and other styles

9

Saigi, Maria, Juan J. Alburquerque-Bejar, and Montse Sanchez-Cespedes. "Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front." Oncogene 38, no. 31 (2019): 5921–32. http://dx.doi.org/10.1038/s41388-019-0855-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Takamori, S., T. Komiya, and E. Powell. "P75.06 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases." Journal of Thoracic Oncology 16, no. 3 (2021): S575—S576. http://dx.doi.org/10.1016/j.jtho.2021.01.1040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Zheng, Aixian, Yanlin Du, Yiru Wang, et al. "CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade." Molecular Therapy - Nucleic Acids 27 (March 2022): 998–1009. http://dx.doi.org/10.1016/j.omtn.2022.01.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Matteucci, Laura, Alessandro Bittoni, Graziana Gallo, Laura Ridolfi, and Alessandro Passardi. "Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?" Cancers 15, no. 21 (2023): 5189. http://dx.doi.org/10.3390/cancers15215189.

Full text

Abstract:

Colorectal cancer (CRC) is the third most frequent cancer and the second leading cause of cancer-related deaths in Europe. About 5% of metastatic CRC (mCRC) are characterized by high microsatellite instability (MSI) due to a deficient DNA mismatch repair (dMMR), and this condition has been related to a high sensitivity to immunotherapy, in particular to the Immune Checkpoint Inhibitors (ICIs). In fact, in MSI-H or dMMR mCRC, treatment with ICIs induced remarkable response rates and prolonged survival. However, the majority of mCRC cases are mismatch-repair-proficient (pMMR) and microsatellite-

APA, Harvard, Vancouver, ISO, and other styles

13

De Pas, Tommaso Martino, Giuseppe Giaccone, Chiara Catania, et al. "First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma." Current Oncology 32, no. 2 (2025): 68. https://doi.org/10.3390/curroncol32020068.

Full text

Abstract:

The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in many solid tumors, particularly in Non-Small Cell Lung Cancer. Although data on the correlation between genetic alterations and response to immunotherapy are available in the majority of common cancers, data are lacking in the subset of patients with KIT-mutated Thymic Carcinoma (TC). As a consequen

APA, Harvard, Vancouver, ISO, and other styles

14

Tuca, Albert, Rosa Gallego, Ismael Ghanem, Mireia Gil-Raga, and Jaime Feliu. "Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer." Journal of Clinical Medicine 9, no. 12 (2020): 4015. http://dx.doi.org/10.3390/jcm9124015.

Full text

Abstract:

Colorectal cancer (CRC) is one of the main causes of cancer death in the elderly. The older patients constitute a heterogeneous group in terms of functional status, comorbidities, and aging-related conditions. Therefore, therapeutic decisions need to be individualized. Additionally, a higher toxicity risk comes from the fact that pharmacokinetics and pharmacodynamics of the drugs as well as the tissue tolerance can be altered with aging. Although the chemotherapy efficacy in metastatic colorectal cancer (mCRC) is similar for older and young patients, more toxicity is presented in the elderly.

APA, Harvard, Vancouver, ISO, and other styles

15

Gambini, Donatella, Stefano Ferrero, and Elisabetta Kuhn. "Lynch Syndrome: From Carcinogenesis to Prevention Interventions." Cancers 14, no. 17 (2022): 4102. http://dx.doi.org/10.3390/cancers14174102.

Full text

Abstract:

Lynch syndrome (LS) is the most common inherited disorder responsible for an increased risk of developing cancers at different sites, most frequently in the gastrointestinal and genitourinary tracts, caused by a germline pathogenic variant affecting the DNA mismatch repair system. Surveillance and risk-reducing procedures are currently available and warranted for LS patients, depending on underlying germline mutation, and are focused on relevant targets for early cancer diagnosis or primary prevention. Although pharmacological approaches for preventing LS-associated cancer development were sta

APA, Harvard, Vancouver, ISO, and other styles

16

Tessema, Belay, Andreas Boldt, Brigitte König, Melanie Maier, and Ulrich Sack. "Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients." HIV/AIDS - Research and Palliative Care Volume 14 (August 2022): 365–79. http://dx.doi.org/10.2147/hiv.s374369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Takamori, S., T. Komiya, and E. Powell. "MA15.07 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age." Journal of Thoracic Oncology 16, no. 10 (2021): S936. http://dx.doi.org/10.1016/j.jtho.2021.08.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Liu, Jinhui, Xing Chen, Yi Jiang, and Wenjun Cheng. "Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer." International Immunopharmacology 86 (September 2020): 106735. http://dx.doi.org/10.1016/j.intimp.2020.106735.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Tierno, Domenico, Gabriele Grassi, Serena Scomersi, et al. "Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications." International Journal of Molecular Sciences 24, no. 11 (2023): 9688. http://dx.doi.org/10.3390/ijms24119688.

Full text

Abstract:

The poor survival of triple-negative breast cancer (TNBC) is due to its aggressive behavior, large heterogeneity, and high risk of recurrence. A comprehensive molecular investigation of this type of breast cancer using high-throughput next-generation sequencing (NGS) methods may help to elucidate its potential progression and discover biomarkers related to patient survival. In this review, the NGS applications in TNBC research are described. Many NGS studies point to TP53 mutations, immunocheckpoint response genes, and aberrations in the PIK3CA and DNA repair pathways as recurrent pathogenic a

APA, Harvard, Vancouver, ISO, and other styles

20

Takamori, Shinkichi, and Takefumi Komiya. "MO1-5 Role of immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients <40 years old of age." Annals of Oncology 34 (November 2023): S1394. http://dx.doi.org/10.1016/j.annonc.2023.09.151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

张, 科宇. "Comparative Analysis of Clinical Characteristics of Patients with Malignant Solid Tumors Treated with and without Immunocheckpoint Inhibitors after COIVD-19 Infection." Advances in Clinical Medicine 15, no. 04 (2025): 1251–58. https://doi.org/10.12677/acm.2025.1541053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Ma, Xiaoting, Yujian Zhang, Shan Wang, and Jing Yu. "Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)." Journal of Cancer 12, no. 2 (2021): 584–94. http://dx.doi.org/10.7150/jca.48105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Saigi, M., J. L. Mate, E. Carcereny, et al. "9MO Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer." Journal of Thoracic Oncology 18, no. 4 (2023): S42. http://dx.doi.org/10.1016/s1556-0864(23)00263-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ma, Ruirui, Xinyi Ma, Xianxin Yan, and Min Ma. "Expression Patterns of Immune Checkpoints in Breast Cancer Patients." Academic Journal of Science and Technology 7, no. 1 (2023): 5–8. http://dx.doi.org/10.54097/ajst.v7i1.10978.

Full text

Abstract:

Background: immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival (OS). Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. Breast cancer (BC) patients are no exception. However, the efficacy of immunocheckpoint therapy in BC patients remains poor. A particularly important factor is the lack of studies on the expression patterns of immune checkpoints in BC patients. Methods：This article summarizes the expression of immune checkpoints such as PD-1, PD-L1, STAT1, CTLA-4 in BC, and analyzes the rela

APA, Harvard, Vancouver, ISO, and other styles

25

Kakizaki, Masatoshi, Yuichiro Yamamoto, Motoyuki Otsuka, et al. "Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model." Journal of Biological Chemistry 295, no. 35 (2020): 12449–60. http://dx.doi.org/10.1074/jbc.ra120.014317.

Full text

Abstract:

Hepatitis B, a viral infection that affects the liver, is thought to affect over 257 million people worldwide, and long-term infection can lead to life-threatening issues such as cirrhosis or liver cancer. Chronic hepatitis B develops by the interaction between hepatitis B virus (HBV) and host immune response. However, questions of how HBV-infected cells thwart immune system defenses remain unanswered. Extracellular vesicles (EVs) are used for cellular communication, carrying cargoes such as RNAs, proteins, and lipids and delivering them intracellularly after being endocytosed by target cells.

APA, Harvard, Vancouver, ISO, and other styles

26

Zhang, Geng, Yi Xu, Sen Zhang, and Huifang Zhou. "The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity." BioMed Research International 2020 (January 9, 2020): 1–9. http://dx.doi.org/10.1155/2020/9756732.

Full text

Abstract:

Nasopharyngeal carcinoma (NPC) is a malignant tumor with poor prognosis, high morbidity, and mortality. Currently, immunocheckpoint therapy has led to new treatment strategies for almost all cancers, including nasopharyngeal carcinoma. Inducible T-cell aggregation ligand (ICOSL) belongs to the b7-cd28 immunoglobulin superfamily, which is a ligand of ICOS, and also begins to draw attention for its potential usage in cancer treatment. Previous studies from our laboratory have suggested that ICOS expression in tumor-infiltrating lymphocytes is correlated with beneficial outcome, but little is kno

APA, Harvard, Vancouver, ISO, and other styles

27

Motadi, Lesetja Raymond. "Abstract 2158: Developing therapeutic strategy to address chemoresistance in cervical cancer using 3D ex vivo sensitivity testing drug." Cancer Research 85, no. 8_Supplement_1 (2025): 2158. https://doi.org/10.1158/1538-7445.am2025-2158.

Full text

Abstract:

Abstract Cervical cancer (CC) is ranked the fourth most common cause of cancer related deaths amongst women. The situation is particularly dire in low to lower middle-income countries. It continues to affect these countries due to poor vaccine coverage and screening. Cervical cancer is mostly detected in the advanced stages leading to poor outcomes. Many different chemotherapy drugs are used to treat recurrent CC, including cisplatin, ifostamide, carboplatin and gemcitabine. These drugs may be used alone or in combination. However, in a country like South Africa limited in resources this has b

APA, Harvard, Vancouver, ISO, and other styles

28

Donisi, Clelia, Andrea Pretta, Eleonora Lai, et al. "Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients." Journal of Clinical Oncology 41, no. 16_suppl (2023): e24020-e24020. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e24020.

Full text

Abstract:

e24020 Background: Aging inevitably leads to an accumulation of senescent cells, and immune system cells aren't an exception. They can contribute to a pro-inflammatory state and be involved in the immune escape of cancer cells through a boosted PD-L1 expression. Immunocheckpoint inhibitors (ICIs) represent the standard of care in several cancer histotypes, and immune-related adverse events (irAEs) seem to be associated with better outcomes. ICIs represent a valid therapeutic agent in elderly patients too. However, there is a lack of data on irAEs and outcomes correlation in this subgroup of pa

APA, Harvard, Vancouver, ISO, and other styles

29

Huang, Wan-Ting, Chee Ho Chew, Amanda Chen, et al. "Abstract 200: Microtube Array Membrane-Hollow Fiber Assay (MTAM-HFA): A combination of immunocheckpoint blocker (ICBs) and secondary drug anti-cancer drug screening system with significant clinical value propositions for personalized medicine and pre-clinical drug development." Cancer Research 82, no. 12_Supplement (2022): 200. http://dx.doi.org/10.1158/1538-7445.am2022-200.

Full text

Abstract:

Abstract Despite modern advances in technology, significant challenges still plague the development of new cancer drugs and cancer care. To address these issue, we are introducing our novel platform technology- Microtube Array Membrane-Hollow Fiber Assay (MTAM-HFA) that is based on combination of the patented MTAM membrane with unique microstructures; replacing the role of traditional hollow fibers enabled the entire HFA assay to be significantly improved in terms of clinical relevance, accuracy, reliability and cost resulting in unprecedented value propositions as an anti-cancer drug screenin

APA, Harvard, Vancouver, ISO, and other styles

30

Salabert, Laura, Marine Gross-Goupil, Thibaud Haaser, Jean-Christophe Bernhard, Jean Palussière, and Alain Ravaud. "Impact of metastatic local treatment in the strategy of metastatic renal cell carinoma including sterotactic radiotherapy, surgery, and radiofrequency in an expert center." Journal of Clinical Oncology 36, no. 6_suppl (2018): 596. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.596.

Full text

Abstract:

596 Background: Standard treatment of metastatic renal clear cell carcinoma is based upon nephrectomy, and systemic treatment with targeted agents. These drugs induce frequent side effects that may compromise observance and quality of life. Considering a focal treatment of one or more metastases can lead to a drug-holidays, or allow to postpone systemic treatment start in oligometastatic disease. Such focal treatment techniques are surgery, radiofrequency ablation (RFA) or stereotactic radiotherapy (SRT). Methods: In this retrospective, monocentric and analytic study, we analyzed progression-f

APA, Harvard, Vancouver, ISO, and other styles

31

Zhou, Chengzhi, Zhanhong Xie, Yinyin Qin, et al. "Genomic profiling of pulmonary lymphoepithelioma-like carcinoma (PLELC)." Journal of Clinical Oncology 37, no. 15_suppl (2019): 1572. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1572.

Full text

Abstract:

1572 Background: PLELC, a rare and distinct type of primary lung cancer, is characterized by Epstein-Barr virus (EBV) infection. Histologically, it resembles undifferentiated nasopharyngeal carcinomas (NPC). Only a few hundred cases have been reported since its discovery. Due to the extreme rareness, its genomic landscape remains elusive. Methods: Tissue samples of 27 PLELC patients (13 males and 14 females) with various stages (Ib to IV) were subjected to targeted sequencing using a panel consisting of 520 cancer-related genes, spanning 1.6Mb of human genome. Results: Collectively, we identif

APA, Harvard, Vancouver, ISO, and other styles

32

Torres-Martínez, Susana, Silvia Calabuig-Fariñas, Sandra Gallach, et al. "Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer." International Journal of Molecular Sciences 24, no. 24 (2023): 17587. http://dx.doi.org/10.3390/ijms242417587.

Full text

Abstract:

Immunotherapy has been proven a viable treatment option for non-small cell lung cancer (NSCLC) treatment in patients. However, some patients still do not benefit. Finding new predictive biomarkers for immunocheckpoint inhibitor (ICI) response will improve treatment management in the clinical routine. In this regard, liquid biopsy is a useful and noninvasive alternative to surgical biopsies. In the present study, we evaluated the potential diagnostic, prognostic, and predictive value of seven different soluble mediators involved in immunoregulation. Fifty-two plasma samples from advanced NSCLC

APA, Harvard, Vancouver, ISO, and other styles

33

Li, Hong, and Jun Yan. "Abstract 6533: Pivotal role of specific LYVE1+ tissue resident macrophages in PDAC progression & immunotherapy resistance." Cancer Research 84, no. 6_Supplement (2024): 6533. http://dx.doi.org/10.1158/1538-7445.am2024-6533.

Full text

Abstract:

Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense fibrotic stroma and abundant myeloid cell infiltration, which render it resistant to any therapeutic interventions, including immunocheckpoint blockade (ICB) therapy. Understanding the composition and function of myeloid cells within the PDAC microenvironment may help identify promising targets for PDAC immunotherapy. Tissue resident macrophages (TRMs) contribute to organogenesis and tissue regeneration and metabolism. In this study, we discovered a distinct population of pancreas TRMs that highly express lymphatic vess

APA, Harvard, Vancouver, ISO, and other styles

34

Massari, Francesco, Matteo Santoni, Chiara Ciccarese, and Daniele Santini. "The immunocheckpoints in modern oncology: the next 15 years." Expert Opinion on Biological Therapy 15, no. 7 (2015): 917–21. http://dx.doi.org/10.1517/14712598.2015.1035251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ndembe, Gloriana, Mirko Marabese, Ilenia Intini, et al. "Abstract 2380: The effect of metabolic alterations on chemo-immunotherapy response in non-small-cell lung cancer model." Cancer Research 82, no. 12_Supplement (2022): 2380. http://dx.doi.org/10.1158/1538-7445.am2022-2380.

Full text

Abstract:

Abstract Introduction: Lung cancer is one of the leading cause of cancer death worldwide, with an estimate incidence of about 2 million new cases per year. Among all lung cancers, non-small-cell lung cancer (NSCLC) is the most frequent (nearly 85%) with a 5-year survival of about 25% when all stages are considered.NSCLCs are frequently mutated in KRAS or STK11/LKB1 and co-mutation is often reported. Considering the key role of STK11/LKB1 in controlling cell metabolism, we hypothesized that NSCLC harboring mutations in this gene could be vulnerable to metabolic stresses. Different studies in th

APA, Harvard, Vancouver, ISO, and other styles

36

Muñoz, L. Gómez, D. Perna Barrull, M. Murillo, and M. Vives Pi. "PR-001. RECUPERACIÓN DE IMMUNOCHECKPOINTS DURANTE LA REMISIÓN PARCIAL DE LA DIABETES TIPO 1: NUEVOS BIOMARCADORES Y DIANAS TERAPÉUTICAS." Endocrinología, Diabetes y Nutrición 72 (April 2025): 1. https://doi.org/10.1016/s2530-0164(25)00105-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Annibali, Ombretta, Monica Di Cecca, Martina Verri, et al. "T Cell Ig and ITIM Domains (TIGIT) Expression in Multiple Myeloma." Blood 142, Supplement 1 (2023): 6607. http://dx.doi.org/10.1182/blood-2023-189171.

Full text

Abstract:

Background Neoplastic myeloma cells show a wide variety of mechanisms that induce the microenvironment, allowing immune evasion and promoting their proliferation, survival, migration and drug resistance. In this context, immunocheckpoints are particularly important, representing the modulators of signal pathways responsible for immune tolerance, a mechanism that prevents the destruction of cancer cells by the immune system. T cell Ig and ITIM domains (TIGIT), a member of the poliovirus (PVR) /nectin receptor family, is a new immune checkpoint that negatively regulates T cell functions. In Mult

APA, Harvard, Vancouver, ISO, and other styles

38

Auletta, Federica, Caterina Ieranò, Giuseppina Rea, et al. "Abstract 7655: The CXCR4/CXCR7/CXCL12 axis and PBRM1 are involved in everolimus resistance in human renal cancer cell lines." Cancer Research 84, no. 6_Supplement (2024): 7655. http://dx.doi.org/10.1158/1538-7445.am2024-7655.

Full text

Abstract:

Abstract Purpose: Renal cell carcinoma (RCC) is one of the most common malignancies in the genitourinary system. Combinations of Immunocheckpoints inhibitors plus TKIs represents the actual standard of therapy for metastatic RCC patients, while mTOR inhibitors play a role in the second-line treatment of mRCC in combination with lenvatinib. Thus characterizing resistance mechanism to mTOR inhibitors is unmet need. Experimental Design: A498 RAD-resistant renal cell carcinoma (RCC) cells were generated through increasing doses of RAD001 (RAD1-5-10 μM). Gene expression was assessed by qRT-PCR. pER

APA, Harvard, Vancouver, ISO, and other styles

39

Li, Lincheng, Zhaoda Deng, Zhaohui Xiao, Wenbo Zou, and Rong Liu. "Analysis of Pyroptosis-Related Signature for Predicting Prognosis and Tumor Immune Microenvironment in Pancreatic Cancer." Frontiers in Oncology 12 (May 31, 2022). http://dx.doi.org/10.3389/fonc.2022.770005.

Full text

Abstract:

Pancreatic cancer (PC) has a poor prognosis, which is attributable to its high aggressiveness and lack of effective therapies. Although immunotherapy has been used for the treatment of various tumor, its efficacy in pancreatic cancer is not satisfactory. As a caspase-1-dependent programmed cell death, pyroptosis s involved in the pathological process of many tumors. Nevertheless, the vital role of the pyroptosis-related gene (PRG) in PC remains unknown. In this study, univariate COX regression was performed for 33 pyroptosis-related genes. Based on these prognosis-related PRGs, all PC patients

APA, Harvard, Vancouver, ISO, and other styles

40

Zhou, Bei, Yan Yang, Yan Kang, Jingjing Hou, and Yun Yang. "Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy." Cell Communication and Signaling 22, no. 1 (2024). http://dx.doi.org/10.1186/s12964-023-01384-x.

Full text

Abstract:

AbstractTumor immunotherapy, which targets immune checkpoints, presents a promising strategy for the treatment of various cancer types. However, current clinical data indicate challenges in its application to solid tumors. Recent studies have revealed a significant correlation between the degree of immune response in immunotherapy and the tumor microenvironment, particularly with regard to tumor-infiltrating immune cells. Among these immune cells, macrophages, a critical component, are playing an increasingly vital role in tumor immunotherapy. This review focuses on elucidating the role of mac

APA, Harvard, Vancouver, ISO, and other styles

41

Hu, Meng, Weirong Yao, and Qinglin Shen. "Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer." Frontiers in Genetics 13 (September 30, 2022). http://dx.doi.org/10.3389/fgene.2022.1005658.

Full text

Abstract:

Primary liver cancer (PLC) is one of the most common malignant tumors, which clinically characterized by occult onset, rapid development, easy recurrence and poor prognosis. With the rapid development of tumor immunotherapy research, tumor immunotherapy has also achieved remarkable clinical efficacy, and jointly promoted the overall improvement of tumor immunology from mechanism research to clinical transformation, from single discipline to multi-disciplinary integration. Immunotherapy has obvious advantages in treatment-related toxicity and efficacy compared with traditional therapy. In hepat

APA, Harvard, Vancouver, ISO, and other styles

42

Zhang, Yu, Lifeng Wang, Rutian Li, and Baorui Liu. "The emerging development of tumor mutational burden in patients with NSCLC." Future Oncology, February 12, 2020. http://dx.doi.org/10.2217/fon-2019-0650.

Full text

Abstract:

Immunocheckpoint inhibitors (ICIs) which target PD-1 and CTLA-4 have dramatically changed the history of non-small-cell lung cancer treatment. Multiple biomarkers especially tumor mutational burden (TMB) have been raised to be potential predictors of response to ICIs. However, great value of TMB has been observed in patients who receive ICIs monotherapy instead of ICIs combination therapy from latest exploratory studies. Thus, the innovative concept of TMB needs to be identified. This study uncovers specific aspects of TMB including signatures of TMB, factors related with variation, racial dif

APA, Harvard, Vancouver, ISO, and other styles

43

Boguszewska-Byczkiewicz, Katarzyna, and Agnieszka Kołacińska-Wow. "Liquid biopsy in targeting gene polymorphism related to the response within immunocheckpoint inhibitors therapeutic regimen." Medical Research Journal, May 10, 2021. http://dx.doi.org/10.5603/mrj.a2021.0022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Liu, Yong, Zhi Yang, Shuanglian Wang, et al. "Nuclear PD-L1 compartmentalization suppresses tumorigenesis and overcomes immunocheckpoint therapy resistance in mice via histone macroH2A1." Journal of Clinical Investigation 134, no. 22 (2024). http://dx.doi.org/10.1172/jci181314.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Zhang, Pengfei, Hu Chen, Chuan Chen, et al. "Bioinspired immuno-radio-enhancers toward synergistic nanomedicine through radiation-induced abscopal effects and immunocheckpoint blockade therapies." Biomaterials Science, 2023. http://dx.doi.org/10.1039/d3bm01144e.

Full text

Abstract:

The use of local radiotherapy in combination with immunotherapy has attracted great interest to obtain local cancer control. A versatile drug delivery platform for an MRI-guided immuno/radio-therapy (RT) strategy, which...

APA, Harvard, Vancouver, ISO, and other styles

46

Zhang, Jun, Yu Xia, Xiaomei Zhou, et al. "Current landscape of personalized clinical treatments for triple-negative breast cancer." Frontiers in Pharmacology 13 (September 16, 2022). http://dx.doi.org/10.3389/fphar.2022.977660.

Full text

Abstract:

Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer (BC) with vicious behaviors. TNBC is usually associated with relatively poor clinical outcomes, earlier recurrence, and high propensity for visceral metastases than other BC types. TNBC has been increasingly recognized to constitute a very molecular heterogeneous subtype, which may offer additional therapeutic opportunities due to newly discovered cancer-causing drivers and targets. At present, there are multiple novel targeted therapeutic drugs in preclinical researches, clinical trial designs, and clinical pr

APA, Harvard, Vancouver, ISO, and other styles

47

Tomarchio, Valeria, and Luigi Rigacci. "Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach." Chemotherapy, September 14, 2023, 1–10. http://dx.doi.org/10.1159/000533766.

Full text

Abstract:

<b><i>Background:</i></b> Positron emission tomography (PET) with the use of 18F-fluorodeoxyglucose (FDG), implemented with low-dosage computer tomography, is to be considered as the most important evolution of imaging in the management and assessment of classical Hodgkin lymphoma patients. <b><i>Summary:</i></b> According to Lugano response criteria, FDG-PET is mandatory to define metabolic response to frontline therapy and moreover it is important in the definition of nonresponders or refractory disease patients. Refractory disease is reported

APA, Harvard, Vancouver, ISO, and other styles

48

Wang, Liguo, Song Han, Changxiang Yan, Yakun Yang, Zhiqiang Li, and Zuocheng Yang. "The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study." Journal of Cancer Research and Clinical Oncology, January 2, 2021. http://dx.doi.org/10.1007/s00432-020-03425-1.

Full text

Abstract:

Abstract Purpose Supratentorial extraventricular ependymoma (SEE) is a rare subset of ependymomas located in the supratentorial parenchyma, and little is known regarding its management and prognosis. Our study aimed to reveal the prognostic factors in patients with SEE and the roles of programmed death ligand-1 (PD-L1), programmed cell death protein 1 (PD-1), Ki-67, and neural cell adhesion molecule L1 (L1CAM) in predicting these patients’ outcomes. Methods We retrospectively studied the clinical features and prognostic factors in 48 patients with SEE admitted to our center from April 2008 to

APA, Harvard, Vancouver, ISO, and other styles

49

Chen, Jierong, Lianghe Lu, Chunhua Qu, et al. "Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy." Frontiers in Medicine 9 (September 20, 2022). http://dx.doi.org/10.3389/fmed.2022.981001.

Full text

Abstract:

Immunocheckpoint inhibitors have shown significant efficacy in the treatment of hepatocellular carcinoma (HCC), but there are individual differences. The aim of this study was to explore body mass index (BMI) as a predictor of anti-PD-1 efficacy in patients with HCC. We retrospectively analyzed 101 HCC patients who treated with anti-PD-1 at Sun Yat-sen University Cancer Center from July 2018 to November 2019 and divided them into overweight (BMI &gt; 24.9) and non-overweight (BMI ≤ 24.9) groups based on baseline BMI levels. BMI &gt; 24.9 accounted for 22 cases (21.8%) and BMI ≤ 24.9 ac

APA, Harvard, Vancouver, ISO, and other styles

50

Shi, Binhao, Junli Chang, Xingyuan Sun, et al. "A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma." Frontiers in Oncology 13 (June 12, 2023). http://dx.doi.org/10.3389/fonc.2023.1148735.

Full text

Abstract:

BackgroundsPD-1 inhibitors and TKIs have been used to treat advanced osteosarcoma, but there is still a lack of intuitive data for the comparison of their efficacy. We conducted a meta-analysis to evaluate their therapeutic benefits.MethodsA systematic methodological search of five primary electronic databases was performed. Studies with a randomized design of any type about PD-1 inhibitors or TKIs for the treatment of advanced osteosarcoma were included. The primary outcomes mainly included CBR, PFS, OS and ORR, The CR, PR, SD and AEs were the secondary outcomes. The survival period (months)

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!